What is the 13F Pro Quality Score for IART?

13F Pro ranks INTEGRA LIFESCIENCES HOLDINGS CORP (IART) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IART's current score at https://13fpro.ai/research/IART (free sign-up required for the full ranking).

Where does 13F Pro source IART data?

All INTEGRA LIFESCIENCES HOLDINGS CORP fundamentals and ownership data come directly from SEC EDGAR. INTEGRA LIFESCIENCES HOLDINGS CORP files with the SEC under CIK 917520. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IART in?

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IART research updated on 13F Pro?

IART's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

INTEGRA LIFESCIENCES HOLDINGS CORP(IART)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 917520 IART stock profile & AI dashboard →

13F Pro Quality Score

31.7/100

Rank #2,300 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

41.8/100

Profitability

12.3/100

Balance Sheet

14.2/100

Earnings Quality

30.0/100

Free Cash Flow

29.2/100

Institutional Flow

26.9/100

Revenue Scale

58.7/100

Dilution Risk

54.0/100

IART Stock Analysis & AI Quality Score

AI stock analysis and institutional research for INTEGRA LIFESCIENCES HOLDINGS CORP (IART), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IART at 31.7/100 on a 32-signal composite quality model, placing it at rank #2,300 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (12.3) and balance sheet strength (14.2), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), INTEGRA LIFESCIENCES HOLDINGS CORP reports quarterly revenue of $391.9M, net income of $-4.6M, free cash flow of $-5.0M. Top institutional holders of IART by reported 13-F value include BlackRock,, Rubric Capital Management, PARADIGM CAPITAL MANAGEMENT /NY, based on the most recent SEC filings. IART trades on the Nasdaq exchange and files with the SEC under CIK 917520. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IART daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for INTEGRA LIFESCIENCES HOLDINGS CORP directly from SEC EDGAR. INTEGRA LIFESCIENCES HOLDINGS CORP's 13F Pro composite quality score has ranged between 31 and 63 since 2021, currently 31.7 — a declining long-term trajectory across 28 quarterly and live scoring snapshots.

✦

Fun facts about INTEGRA LIFESCIENCES HOLDINGS CORP

Quirks, history, and lore behind IART — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · mid-cap · listed on Nasdaq · headquartered in New Jersey.
2
The Numbers
Annual revenue in the range of $1.5 billion, built across two main segments: Codman Specialty Surgical and Orthopedics and Tissue Technologies.
3
The History
Founded in 1989, it grew aggressively through acquisitions — including snagging the storied Codman neurosurgery brand from Johnson & Johnson.
4
The Secret
It's a major player in neurosurgery and regenerative medicine — including products that help regrow tissue over damaged nerves and skin, which sounds like science fiction but isn't.
5
The Lore
Its DuraSeal product seals the membrane around your brain and spinal cord after surgery — not a dinner-party conversation starter, but a genuinely life-saving sealant.
6
The Giveaway
Its ticker is IART, and its full name rhymes with nothing easy — but if you've ever had neurosurgery or reconstructive tissue repair, there's a good chance this New Jersey medtech firm's products were in the room.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$391.9M

Net Income

Q1 2026

$-4.6M

Free Cash Flow

Q1 2026

$-5.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+1.5% YoY

$1.64BFY 2025

FY20 $1.37BFY22 $1.56BFY24 $1.61BFY25 $1.64B

Net Income

-7342.4% YoY

$-516.8MFY 2025

FY20 $133.9MFY22 $180.6MFY24 $-6.9MFY25 $-516.8M

Operating Income

-1836.5% YoY

$-493.4MFY 2025

FY20 $151.4MFY22 $238.9MFY24 $28.4MFY25 $-493.4M

EPS (Diluted)

-7388.9% YoY

$-6.74FY 2025

FY20 $1.57FY22 $2.16FY24 $-0.09FY25 $-6.74

Total Assets

-10.8% YoY

$3.60BFY 2025

FY20 $3.62BFY22 $3.89BFY24 $4.04BFY25 $3.60B

Total Debt

-4.5% YoY

$726.6MFY 2025

FY20 $877.5MFY22 $775.0MFY24 $760.5MFY25 $726.6M

Op. Cash Flow

-61.1% YoY

$50.4MFY 2025

FY20 $203.8MFY22 $264.5MFY24 $129.4MFY25 $50.4M

Metric	FY 2025	FY 2024	FY 2022	FY 2020	FY 2019	FY 2018
Revenue	$1.64B +1.5%	$1.61B +3.4%	$1.56B +13.5%	$1.37B -9.6%	$1.52B +3.1%	$1.47B
Net Income	$-516.8M -7342.4%	$-6.9M -103.8%	$180.6M +34.8%	$133.9M +166.7%	$50.2M -17.4%	$60.8M
Operating Income	$-493.4M -1836.5%	$28.4M -88.1%	$238.9M +57.8%	$151.4M +61.4%	$93.8M -15.5%	$111.0M
EPS (Diluted)	$-6.74 -7388.9%	$-0.09 -104.2%	$2.16 +37.6%	$1.57 +170.7%	$0.58 -19.4%	$0.72
Total Assets	$3.60B -10.8%	$4.04B +3.8%	$3.89B +7.6%	$3.62B +9.4%	$3.30B +6.3%	$3.11B
Total Debt	$726.6M -4.5%	$760.5M -1.9%	$775.0M -11.7%	$877.5M +0.0%	$877.5M -2.5%	$900.0M
Operating Cash Flow	$50.4M -61.1%	$129.4M -51.1%	$264.5M +29.7%	$203.8M -11.9%	$231.4M +15.9%	$199.7M

Get alerted when IART's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for INTEGRA LIFESCIENCES HOLDINGS CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IART

BlackRock, Inc.
$97.2M10,319,169 sh
Rubric Capital Management LP
$73.0M7,753,934 sh
PARADIGM CAPITAL MANAGEMENT INC/NY
$37.8M4,012,698 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$34.7M3,686,637 sh
MORGAN STANLEY
$33.8M3,584,155 sh
FULLER & THALER ASSET MANAGEMENT, INC.
$33.2M3,529,404 sh
Invesco Ltd.
$32.8M3,485,603 sh
VANGUARD CAPITAL MANAGEMENT LLC
$27.2M2,890,824 sh
STATE STREET CORP
$27.2M2,886,556 sh
DIMENSIONAL FUND ADVISORS LP
$26.1M2,774,988 sh

Fund	Value	Shares
BlackRock, Inc.	$97.2M	10,319,169
Rubric Capital Management LP	$73.0M	7,753,934
PARADIGM CAPITAL MANAGEMENT INC/NY	$37.8M	4,012,698
VANGUARD PORTFOLIO MANAGEMENT LLC	$34.7M	3,686,637
MORGAN STANLEY	$33.8M	3,584,155
FULLER & THALER ASSET MANAGEMENT, INC.	$33.2M	3,529,404
Invesco Ltd.	$32.8M	3,485,603
VANGUARD CAPITAL MANAGEMENT LLC	$27.2M	2,890,824
STATE STREET CORP	$27.2M	2,886,556
DIMENSIONAL FUND ADVISORS LP	$26.1M	2,774,988

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IART on your watchlist

Track score changes the day INTEGRA LIFESCIENCES HOLDINGS CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IART a good stock to buy?

13F Pro's AI-powered analysis of INTEGRA LIFESCIENCES HOLDINGS CORP (IART) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IART are available on the IART stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IART?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IART. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of INTEGRA LIFESCIENCES HOLDINGS CORP's investment landscape.